STOCK TITAN

Glaukos Corporation (GKOS) Financials

GKOS NYSE
Trailing 12 months to June 30, 2026
Revenue $612.8M +41.5% YoY
Net Income -$188.0M n/m YoY
EPS (Diluted) -$3.26 n/m YoY
Free Cash Flow -$12.2M n/m YoY
Market Cap $10.7B as of Oct 27, 2026
Price / Sales 17.4x on $612.8M revenue, trailing 12 months to June 30, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026
Price / Book 15.7x on $682.5M equity, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Jul 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GKOS SEC filings page.

Glaukos Corporation (GKOS) reported $612.8M in revenue over the twelve months to Jun 30, 2026, up 41.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI GKOS FY2025

FY2025 growth exposed a margin squeeze: revenue expanded, but gross profit fell as costs rose faster than sales.

The gap between a net loss of $187.7M and operating cash flow of -$14.8M means reported earnings were far more negative than cash movement. Receivables rose 78.8%, so the smaller cash shortfall does not mean earnings converted to cash; working capital was a meaningful offset.

Revenue rose 32.3% in FY2025, yet gross profit fell to $282.8M. Gross margin dropped 19.8 percentage points to 55.7%, indicating margin compression rather than better economics from scale.

SG&A reached $331.7M while R&D was $150.6M, so the two largest operating expense pools together exceeded the gross-profit base. That structure produced an operating loss of $199.6M despite sales growth, showing that expansion was being absorbed before reaching operating earnings.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 51 / 100
Financial Health Score 51/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Glaukos Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
24

Glaukos Corporation has an operating margin of -39.3%, meaning the company loses $39 on every $100 of revenue. This results in a profitability score of 24/100. This is down from -31.9% the prior year.

Growth
88

Glaukos Corporation's revenue surged 32.3% year-over-year to $507.4M, reflecting rapid business expansion. This strong growth earns a score of 88/100.

Leverage
66
Liquidity
90

With a current ratio of 4.69, Glaukos Corporation holds $4.69 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 90/100.

Cash Flow
11

Glaukos Corporation's operations used $14.8M of cash, and capex of $7.7M added to the outflow, for a free cash flow shortfall of $22.5M. This results in a cash flow score of 11/100.

Returns
24

Glaukos Corporation posts a -28.6% return on equity (ROE), meaning it loses $29 for every $100 of shareholders' equity. This results in a returns score of 24/100. This is down from -19.1% the prior year.

Altman Z-Score Safe
25.89

Glaukos Corporation scores 25.89, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $10.7B against total liabilities of $237.3M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
2/8

Glaukos Corporation passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 operating efficiency signals passes.

Earnings Quality No Cash Backing
N/A

Glaukos Corporation reported a net loss of $187.7M while operations used $14.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

Glaukos Corporation reported an operating loss of $199.6M against $4.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$185.6M
YoY+49.5%
QoQ+23.3%
5Y CAGR+18.9%
10Y CAGR+20.6%

Glaukos Corporation generated $185.6M in revenue in Q2 2026. This represents an increase of 49.5% from the same quarter a year earlier. Against the prior quarter it is up 23.3%.

EBITDA
-$8.4M
YoYn/m
QoQn/m

Glaukos Corporation's EBITDA was -$8.4M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$18.4M
YoYn/m
QoQn/m
5Y CAGRn/m

Glaukos Corporation reported a net loss of $18.4M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.31
YoYn/m
QoQn/m
5Y CAGRn/m

Glaukos Corporation earned -$0.31 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
$12.1M
YoY+108.4%
QoQn/m
5Y CAGRn/m
10Y CAGR+8.8%

Glaukos Corporation generated $12.1M in free cash flow in Q2 2026, representing cash available after capex. This represents an increase of 108.4% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$114.5M
YoY+13.6%
QoQ+9.8%
5Y CAGR-0.7%
10Y CAGR+25.0%

Glaukos Corporation held $114.5M in cash as of Q2 2026; no long-term debt figure is on record for that period.

Shares Outstanding
59M
YoY+2.8%
QoQ+0.4%
5Y CAGR+4.8%
10Y CAGR+6.0%

Glaukos Corporation had 59M shares outstanding in Q2 2026. This represents an increase of 2.8% from the same quarter a year earlier. Against the prior quarter it is up 0.4%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin
81.7%
YoY+3.3pp
QoQ+3.8pp
5Y change+4.4pp
10Y change-3.1pp

Glaukos Corporation's gross margin was 81.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 3.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.8 percentage points.

Operating Margin
-9.3%
YoY+9.0pp
QoQ+3.9pp
5Y change+8.9pp
10Y change-16.7pp

Glaukos Corporation's operating margin was -9.3% in Q2 2026, reflecting core business profitability. This is up 9.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.9 percentage points.

Net Margin
-9.9%
YoY+5.9pp
QoQ+3.2pp
5Y change+12.5pp
10Y change-18.1pp

Glaukos Corporation's net profit margin was -9.9% in Q2 2026, showing the share of revenue converted to profit. This is up 5.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.2 percentage points.

Return on Equity
-2.7%
YoY-0.1pp
QoQ+0.3pp
5Y change+0.3pp
10Y change-4.9pp

Glaukos Corporation's quarterly ROE was -2.7% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 0.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.3 percentage points.

Capital Allocation

R&D Spending
$51.3M
YoY+40.4%
QoQ+16.2%
5Y CAGR+16.2%
10Y CAGR+22.1%

Glaukos Corporation invested $51.3M in research and development in Q2 2026. This represents an increase of 40.4% from the same quarter a year earlier. Against the prior quarter it is up 16.2%.

Capital Expenditures
$2.7M
YoY+132.2%
QoQ-30.8%
5Y CAGR-24.8%
10Y CAGR+12.5%

Glaukos Corporation invested $2.7M in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 132.2% from the same quarter a year earlier. Against the prior quarter it is down 30.8%.

Share Buybacks

Not reported for Q2 2026.

GKOS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GKOS quarterly income statement
MetricQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Revenue$185.6M+49.5%$150.6M+41.2%$143.1M+35.7%$133.5M+38.1%$124.1M+29.7%$106.7M+24.6%$105.5M+28.1%$96.7M+23.9%
Cost of Revenue$34.0M+26.5%$33.3M+37.1%$31.8M+11.0%$28.8M+27.7%$26.9M+19.3%$24.3M+20.0%$28.6M+51.6%$22.6M+22.0%
Gross Profit$151.6M+55.9%$117.2M+42.4%$111.3M+44.9%$104.7M+41.3%$97.2M+32.9%$82.3M+26.0%$76.9M+21.1%$74.1M+24.4%
R&D Expenses$51.3M+40.4%$44.1M+36.4%$43.7M+19.5%$38.1M+9.6%$36.5M+6.1%$32.4M+5.3%$36.5M-1.4%$34.7M+4.3%
SG&A Expenses$116.1M+39.2%$92.9M+31.5%$94.7M+37.2%$83.0M+29.7%$83.4M+26.0%$70.7M+14.0%$69.0M+9.5%$64.0M+18.0%
Operating Income-$17.3Mn/m-$19.9Mn/m-$139.9Mn/m-$16.4Mn/m-$22.7Mn/m-$20.7Mn/m-$28.7Mn/m-$24.7Mn/m
EBITDA-$8.4Mn/m-$8.1Mn/m-$127.7Mn/m-$7.2Mn/m-$14.1Mn/m-$12.5Mn/m-$19.9Mn/m-$15.7Mn/m
Interest Expense$1.5M+26.8%$1.1M-3.3%$1.1M-27.1%$1.2M-29.3%$1.2M-65.7%$1.2M-66.3%$1.6M-54.1%$1.7M-51.1%
Income Tax$656K+164.5%$484K+48.5%-$6.2Mn/m$234K+32.2%$248K-25.1%$326K-13.5%-$114K-286.9%$177K+378.4%
Net Income-$18.4Mn/m-$19.8Mn/m-$133.7Mn/m-$16.2Mn/m-$19.7Mn/m-$18.1Mn/m-$33.6Mn/m-$21.4Mn/m
EPS (Basic)-$0.31n/m-$0.34n/m-$2.33n/m-$0.28n/m-$0.34n/m-$0.32n/m-$0.59n/m-$0.39n/m
EPS (Diluted)-$0.31n/m-$0.34n/m-$2.33n/m-$0.28n/m-$0.34n/m-$0.32n/m-$0.59n/m-$0.39n/m
Diluted Shares (Avg)59M+2.8%58M+2.4%N/A57M+4.3%57M+12.8%57M+14.2%N/A55M+13.1%

GKOS Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GKOS quarterly balance sheet
MetricQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Total Assets$920.5M-6.7%$893.3M-7.5%$893.5M-8.3%$999.4M+7.9%$987.0M+7.3%$966.2M+3.5%$974.8M+3.7%$926.5M-2.3%
Current Assets$515.8M+18.3%$485.8M+9.3%$475.0M+5.6%$454.8M+14.5%$436.1M+13.6%$444.5M+14.4%$449.8M+13.7%$397.3M-0.6%
Cash & Equivalents$114.5M+13.6%$104.2M-8.8%$90.8M-46.5%$98.2M-1.9%$100.8M+48.1%$114.3M+168.9%$169.6M+81.5%$100.1M-8.1%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Inventory$59.3M-8.2%$62.4M+4.9%$63.6M+10.2%$63.9M+6.6%$64.6M+14.4%$59.5M+18.5%$57.7M+37.4%$59.9M+50.6%
Accounts Receivable$138.9M+67.4%$119.7M+67.3%$108.6M+78.8%$98.7M+74.9%$83.0M+62.0%$71.5M+53.7%$60.7M+52.4%$56.4M+43.4%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Goodwill$66.7M0.0%$66.7M+0.9%$66.7M+0.9%$66.7M+0.9%$66.7M+0.9%$66.1M0.0%$66.1M0.0%$66.1M0.0%
Total Liabilities$238.0M+7.3%$222.4M+10.0%$237.3M+14.2%$229.8M-10.9%$221.8M-12.8%$202.2M-58.1%$207.8M-56.6%$258.0M-45.2%
Current Liabilities$102.3M+29.3%$89.4M+30.5%$101.3M+34.8%$87.5M+22.1%$79.1M+12.9%$68.5M-5.1%$75.1M+1.5%$71.7M+6.8%
Non-Current Liabilities$135.7M-4.9%$133.0M-0.5%$136.1M+2.5%$142.3M-23.6%$142.7M-22.6%$133.7M-67.4%$132.7M-67.2%$186.3M-53.9%
Long-Term DebtN/AN/AN/AN/AN/AN/AN/A$56.8M-79.9%
Total Equity$682.5M-10.8%$670.9M-12.2%$656.2M-14.4%$769.5M+15.1%$765.1M+15.0%$764.0M+69.5%$766.9M+66.1%$668.5M+40.0%
Retained Earnings-$971.3Mn/m-$952.9Mn/m-$933.1Mn/m-$799.5Mn/m-$783.2Mn/m-$763.6Mn/m-$745.4Mn/m-$711.9Mn/m

GKOS Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GKOS quarterly cash flow statement
MetricQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Operating Cash Flow$14.8M+112.4%-$12.5Mn/m$6.8M+1249.7%-$10.1Mn/m$7.0Mn/m-$18.5Mn/m$507Kn/m-$9.6Mn/m
Depreciation & Amortization$8.9M+3.5%$11.8M+43.4%$12.2M+39.2%$9.1M+1.5%$8.6M-4.8%$8.2M-7.7%$8.7M+2.6%$9.0M+6.4%
Stock-Based Compensation$28.9M+60.2%$19.1M+47.4%N/A$14.9M+3.4%$18.0M+59.3%$13.0M+16.3%N/A$14.4M+37.5%
Capital Expenditures$2.7M+132.2%$4.0M+104.3%$2.9M+68.1%$1.6M+12.8%$1.2M-45.1%$1.9M+100.2%$1.7M-58.9%$1.4M-56.8%
Free Cash Flow$12.1M+108.4%-$16.5Mn/m$3.9Mn/m-$11.7Mn/m$5.8Mn/m-$20.5Mn/m-$1.2Mn/m-$11.0Mn/m
Investing Cash Flow-$5.3Mn/m$10.5Mn/m-$15.9M-234.8%-$4.0M-113.1%-$20.8M-159.6%-$36.9Mn/m$11.8Mn/m$30.6M+105.2%
Financing Cash Flow$991K-55.9%$15.8M+708.7%$2.4M-96.0%$5.3M-45.6%$2.2M-73.9%$1.9M-85.2%$60.1M+723.1%$9.7M+29.5%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

GKOS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

GKOS quarterly financial ratios
MetricQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-Q
Gross Margin81.7%+3.3pp77.9%+0.7pp77.8%+4.9pp78.4%+1.8pp78.3%+1.9pp77.2%+0.9pp72.9%-4.2pp76.6%+0.4pp
Operating Margin-9.3%+9.0pp-13.2%+6.2pp-97.7%-70.6pp-12.3%+13.3pp-18.3%+13.0pp-19.4%+26.2pp-27.2%+19.7pp-25.5%+10.4pp
Net Margin-9.9%+5.9pp-13.1%+3.9pp-93.4%-61.6pp-12.2%+10.0pp-15.8%+37.0pp-17.0%+30.7pp-31.8%+12.8pp-22.1%+16.9pp
Return on Equity-2.7%-0.1pp-2.9%-0.6pp-20.4%-16.0pp-2.1%+1.1pp-2.6%+5.0pp-2.4%+6.7pp-4.4%+3.6pp-3.2%+3.2pp
Return on Assets-2.0%0.0pp-2.2%-0.3pp-15.0%-11.5pp-1.6%+0.7pp-2.0%+3.5pp-1.9%+2.5pp-3.4%+0.5pp-2.3%+0.9pp
Current Ratio5.04-0.5x5.43-1.1x4.69-1.3x5.20-0.3x5.510.0x6.49+1.1x5.99+0.6x5.54-0.4x
Debt-to-EquityN/AN/AN/AN/AN/AN/AN/A0.08-0.5x
Liabilities-to-Equity0.35+0.1x0.33+0.1x0.36+0.1x0.30-0.1x0.29-0.1x0.26-0.8x0.27-0.8x0.39-0.6x
Asset Turnover0.20+0.1x0.17+0.1x0.16+0.1x0.130.0x0.130.0x0.110.0x0.110.0x0.100.0x
FCF Margin6.5%+1.8pp-10.9%+8.2pp2.8%+3.9pp-8.8%+2.6pp4.7%+26.1pp-19.2%+21.5pp-1.2%+16.9pp-11.4%+3.4pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Glaukos Corporation GKOS FY2025 $507.4M -$187.7M -37.0% $10.7B 51/100
Bruker Corporation BRKR FY2025 $3.4B -$8.6M -0.3% $8.9B 43/100
TransMedics Group, Inc. TMDX FY2025 $605.5M $190.3M 31.4% $2.4B 56/100
iRhythm Holdings, Inc. IRTC FY2025 $747.1M -$44.6M -6.0% $4.0B 44/100
Integer Holdings Corporation ITGR FY2025 $1.9B $102.8M 5.5% $4.3B 58/100
GLOBUS MEDICAL INC GMED FY2025 $2.9B $537.9M 18.3% $11.0B 77/100

Frequently Asked Questions

What is Glaukos Corporation's annual revenue?

Glaukos Corporation (GKOS) reported $507.4M in total revenue for fiscal year 2025. This represents a 32.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Glaukos Corporation's revenue growing?

Glaukos Corporation (GKOS) revenue grew by 32.3% year-over-year, from $383.5M to $507.4M in fiscal year 2025.

Is Glaukos Corporation profitable?

No, Glaukos Corporation (GKOS) reported a net loss of $188.0M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $187.7M, with a net profit margin of -37.0%.

Glaukos Corporation (GKOS) reported diluted earnings per share of -$3.28 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Glaukos Corporation (GKOS) had EBITDA of -$161.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Glaukos Corporation (GKOS) had a gross margin of 55.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

Glaukos Corporation (GKOS) had an operating margin of -39.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

Glaukos Corporation (GKOS) had a net profit margin of -37.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

Glaukos Corporation (GKOS) has a return on equity of -28.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Glaukos Corporation (GKOS) recorded an outflow of $22.5M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Glaukos Corporation (GKOS) recorded an outflow of $14.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Glaukos Corporation (GKOS) had $893.5M in total assets as of fiscal year 2025, including both current and long-term assets.

Glaukos Corporation (GKOS) invested $7.7M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Glaukos Corporation (GKOS) invested $150.6M in research and development during fiscal year 2025.

Glaukos Corporation (GKOS) had 58M shares outstanding as of fiscal year 2025.

Glaukos Corporation (GKOS) had a current ratio of 4.69 as of fiscal year 2025, which is generally considered healthy.

Glaukos Corporation (GKOS) had a liabilities-to-equity ratio of 0.36 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Glaukos Corporation (GKOS) had a return on assets of -21.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Glaukos Corporation (GKOS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $10.7B as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Glaukos Corporation (GKOS) trades at 17.4x sales, its market capitalization divided by $612.8M revenue, trailing 12 months to June 30, 2026. The market capitalization is $10.7B as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Glaukos Corporation (GKOS) held $90.8M in cash, cash equivalents and investments, and reported an operating cash outflow of $14.8M over that year. Dividing the one by the other, the reported balance equals about 74 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Glaukos Corporation (GKOS) has an Altman Z-Score of 25.89, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Glaukos Corporation (GKOS) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Glaukos Corporation (GKOS) reported a net loss of $187.7M while operations used $14.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Glaukos Corporation (GKOS) reported an operating loss of $199.6M against $4.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Glaukos Corporation (GKOS) scores 51 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top